Aldevron, LLC products

In Stock, Royalty-Free, Helper Plasmid Solution for Recombinant AAV Manufacturing. Triple transfection is the most common method for rAAV production and does not require co-infection with adenovirus; a helper plasmid provides adenoviral genes. Aldevron`s pALD-HELP has several advantages: Immediately available at research grade and GMP-Source Royalty free, including for commercial products. Replaces any rAAV helper plasmid. Kanamycin resistance. Consistent, reliable supply.

In Stock, Royalty-Free, Helper Plasmid Solution for Recombinant AAV Manufacturing. Triple transfection is the most common method for rAAV production and does not require co-infection with adenovirus; a helper plasmid provides adenoviral genes. Aldevron`s pALD-HELP has several advantages: Immediately available at research grade and GMP-Source Royalty free, including for commercial products. Replaces any rAAV helper plasmid. Kanamycin resistance. Consistent, reliable supply. With Aldevron`s pALD-X80, clients do not need to manufacture a custom batch of the helper plasmid as Aldevron maintains it as an in-stock product, reducing timeline and cost.

Recombinant AAV (rAAV) manufacturing is composed of four main parts which include a rep/cap plasmid, a helper plasmid, an expression plasmid, and a viral packaging cell line. Triple transfection of the three plasmids into HEK293 cells is the most frequently used rAAV production method.

Recombinant AAV (rAAV) manufacturing is comprised of four main parts which include a rep/cap plasmid, a helper plasmid, an expression plasmid, and a viral packaging cell line. Triple transfection of the three plasmids into HEK293 cells is the most frequently used rAAV production method. Aldevron now offers reporter plasmids and cloning vectors specifically for rAAV manufacturing.

A simple solution from R&D to clinical material. Aldevron provides research grade Cas9 nucleases for use in development work as well as standard GMP products for clinical studies. The concentration for these products is 10 mg/mL, dispensed in the following sizes: Research Grade: 0.25 mg and 5 mg vials. GMP: 10 mg and 50 mg vials.

Our in vitro transcription (IVT) enzymes are qualified both by activity assays and functionally for RNA synthesis and can be custom manufactured to meet your specific project requirements from milligram to multigram scale. View the table below for a summary of our IVT enzymes.

pCMV-S (also known as pRc/CMV-HBs) is widely used to validate DNA vaccine delivery and formulation strategies. This plasmid expresses the hepatitis B surface antigen (HBsAg) under the control of the CMV immediate-early promoter. pCMVHB-S2.S expresses the small and middle forms of recombinant HBsAg. The plasmid can be used to generate anti-HBsAg antibodies like pCMV-S. It is also used to fuse other sequences to the S form of HBsAg.

The gWiz plasmids are designed for the highest level of gene expression in a wide range of mammalian cells and tissues. They contain a proprietary modified promoter, followed by intron A from the CMV immediate early gene, and a high-efficiency artificial transcription terminator. gWiz expression vectors are constructed using a plasmid backbone that has been extensively modified to achieve enhanced levels of transgene expression in mammalian cells.

Aldevron provides pALD Lenti packaging plasmids through our partnership with OXGENE, who have optimized them for lentiviral vector production.  They are immediately available at all quality levels, eliminating the need to manufacture custom batches. This reduces your costs and significantly reduces time to manufacture vectors for clinical trials.

Find the Right Backbone for your Application. Aldevron, your trusted partner since 1998, has several cloning backbones available. These cloning backbones are empty vectors that can be modified to fit your needs. Each vector is available at research grade and is royalty and license free from research through commercial applications. pALD-CV42 and pALD-CV77 are ideal for researchers who do not have a cloning backbone available. This construct set is appropriate for a wide range of applications. Researchers have also used the pALD-CV77 backbone sequence successfully in clinical trials.